Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the ...

Kevin Simpson of Capital Wealth Planning said Meta Platforms, Inc. META -2.04% Get Free Report is his top pick out of the Mag ...

Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $76 and keeps a Buy rating on the shares.

Elahere, which recorded sales of $479 million in 2024, is approved for some patients with PROC whose cancer exhibits high levels of a specific protein. Corcept's trial hit a home run, H.C ...

Eli Lilly and Company, Corcept Therapeutics, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks represent the publicly ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...